Chimeric Therapeutics Limited
CHM.ASXHealth Care
Chimeric is a biotechnology company developing a cancer cell therapy drug
Market Data
$0.103
+0.0%$5.3M
-100000.0x
$-0.769
0.00%
-0.7%
Latest Earnings
Half Year Report and Appendix 4D 31 December 2025
27 February 2026
Chimeric Therapeutics reported a significantly larger loss of $11.2M for H1 FY2026 (vs $2.9M in H1 FY2025), primarily driven by a $9.75M impairment of intellectual property related to the CHM Chlorotoxin asset returned to City of Hope post-period. The company secured $8.4M in new funding (placement and convertible note) and achieved encouraging clinical progress in its lead CHM CDH17 CAR-T program, but faces material going concern uncertainty with only $2.5M cash remaining and significant ongoing clinical development costs. Key points: CHM CDH17 CAR-T program showing encouraging clinical activity: 75% disease control at 28 days in evaluable population; two CRC patients with stable disease at 13 and 9 months respectively; 100% stable disease at Dose Level 2 under RECIST 1.1 criteria; FDA Orphan Drug Designation granted for CHM CDH17 in gastric cancer, providing development incentives and potential market exclusivity; CORE-NK allogeneic NK cell platform demonstrating strong response rates (57% clinical response in frontline high-risk AML) with favourable safety profile in ADVENT-AML Phase 1b study
Recent Announcements
Half Year Report and Appendix 4D 31 December 2025
Chimeric Therapeutics reported a significantly larger loss of $11.2M for H1 FY2026 (vs $2.9M in H1 FY2025), primarily driven by a $9.75M impairment of intellectual property related to the CHM Chlorotoxin asset returned to City of Hope post-period. The company secured $8.4M in new funding (placement and convertible note) and achieved encouraging clinical progress in its lead CHM CDH17 CAR-T program, but faces material going concern uncertainty with only $2.5M cash remaining and significant ongoing clinical development costs. Key points: CHM CDH17 CAR-T program showing encouraging clinical activity: 75% disease control at 28 days in evaluable population; two CRC patients with stable disease at 13 and 9 months respectively; 100% stable disease at Dose Level 2 under RECIST 1.1 criteria; FDA Orphan Drug Designation granted for CHM CDH17 in gastric cancer, providing development incentives and potential market exclusivity; CORE-NK allogeneic NK cell platform demonstrating strong response rates (57% clinical response in frontline high-risk AML) with favourable safety profile in ADVENT-AML Phase 1b study
Get real-time alerts for CHM
Receive AI-powered earnings summaries and instant notifications when Chimeric Therapeutics Limited releases results.
Register Free